Stem Cell Collaboration and Licensing Deals 2010-2026

Stem Cell Collaboration and Licensing Deals provides the reader with the following key benefits:

•    Understand deal trends since 2010
•    Browse stem cell collaboration and licensing deals
•    Benchmark analysis – identify market value of transactions
•    Financials terms - upfront, milestone, royalties
•    Directory of deals by company A-Z, deal type and therapy area
•    Leading deals by value
•    Most active dealmakers
•    Identify assets and deal terms for each transaction
•    Access contract documents - insights into deal structures
•    Due diligence - assess suitability of your proposed deal terms for partner companies
•    Save hundreds of hours of research time

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in stem cell dealmaking
2.1. Introduction
2.2. Stem cell deals over the years
2.3. Most active stem cell dealmakers
2.4. Stem cell deals by deal type
2.5. Stem cell deals by therapy area
2.6. Stem cell deals by industry sector
2.7. Deal terms for stem cell deals
2.7.1 Stem cell deals headline values
2.7.2 Stem cell deal upfront payments
2.7.3 Stem cell deal milestone payments
2.7.4 Stem cell royalty rates

Chapter 3 – Leading stem cell deals
3.1. Introduction
3.2. Top stem cell deals by value

Chapter 4 – Most active stem cell dealmakers
4.1. Introduction
4.2. Most active stem cell dealmakers
4.3. Most active stem cell deals company profiles

Chapter 5 – Stem cell contracts dealmaking directory
5.1. Introduction
5.2. Stem cell contracts dealmaking directory

Chapter 6 – Stem cell dealmaking by technology type

Deal directory

Deal directory – Stem cell deals by company A-Z
Deal directory – Stem cell deals by deal type
Deal directory – Stem cell deals by therapy area

Deal type definitions

About Biopharma Research Ltd    
Current Partnering
Current Agreements
Recent report titles from Current Partnering

 
Table of figures

Figure 1: Stem cell deals since 2010
Figure 2: Active stem cell dealmaking activity
Figure 3: Stem cell deals by deal type since 2010
Figure 4: Stem cell deals by therapy area since 2010
Figure 5: Stem cell deals by industry sector since 2010
Figure 6: Stem cell deals with a headline value
Figure 7: Stem cell deals with an upfront value
Figure 8: Stem cell deals with a milestone value
Figure 9: Stem cell deals with a royalty rate value
Figure 10: Top stem cell deals by value since 2010
Figure 11: Most active stem cell dealmakers
Figure 12: Stem cell deals by technology type since 2010

Pricing options

• $3,995: single-user (encrypted file - one user/device)
• $5,995: multi-user (encrypted file - up to 5 users/devices)
• $7,995: company (unencrypted PDF)

Single and Multi-user license files are encrypted PDF documents. Details of how to access using Javelin3 PDF Reader will be provided at report delivery.

Company license files are not encrypted and can be accessed using a PDF Reader.

A full explanation of license type definitions can be found here.

 

Our guarantee

 

Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.

 

Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.

 

Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

 

Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.

A*STAR Agency for Science, Technology and Research, A*STAR Genome Institute of Singapore, Aastrom Biosciences, ABT Holding Company, Abu Dhabi Stem Cells Center, Accelerated Biosciences, Accellta, Access BIO, Access Pharmaceuticals, ACEA Biosciences, Actinium Pharmaceuticals, Admedus, AdnaGen, Advanced BioScience Laboratories, Advanced Cell Technology, Aelan Cell Technologies, Affomix, Agathos Biologics, AGC Asahi Glass, Ageless Biotech, Ageless Regenerative, AgeX Therapeutics, Agilent Technologies, AiVita Biomedical, Akadeum Life Sciences, Albert Einstein College of Medicine, Alkem Laboratories, Allele Biotechnology and Pharmaceuticals, AlloSource, ALS Therapy Development Institute, Amedica, American CryoStem, American Society of Hematology, American Type Culture Collection (ATCC), Amgen, Angel Biotechnology, Angioblast Systems, Angiocrine Bioscience, Angionetics, Angiostem, Anthony Nolan, Antitope, Apceth, Aratana Therapeutics, Arbor Biotechnologies, Ariana Pharma, Array Biopharma, Arteriocyte Medical Systems, Arthrex, Ascendance Biotechnology, Astellas Pharma, Asterand Bioscience, Asterias Biotherapeutics, AstraZeneca, ATEC Spine, Athersys, ATMI LifeSciences, Australian Research Council, AuxoCell Laboratories, Axcelead Drug Discovery Partners, Axiogenesis, AXM Pharma, AxoSim, Bakulev Center of Cardiovascular Surgery of Russian Academy of Sciences, Barbara Ann Karmanos Cancer Institute, Bayer Innovation, Bayer Schering Pharma, Baylor Research Institute, BD Biosciences, Beckman Research Institute of City of Hope, Becton Dickinson, Beijing Genomics Institute (BGI), Berlin-Brandenburg Center for Regenerative Therapies, Be The Match BioTherapies, Bill and Melinda Gates Foundation, Bio-Techne, BioCardia, Biocompatibles International, Biocrates, Biocrea, BioDlogics, BioEclipse Therapeutics, Biogalenys, Biogen, BioHeart, Biokine Therapeutics, BioLamina, BiolineRX, Biological Industries, Biomed, Biomodels, Bioneer, BioPontis Alliance, bioRASI, BioRestorative Therapies, BioSante Pharmaceuticals, Biotech Products Services & Research, BlueRock Therapeutics, Boehringer Ingelheim, Bone Therapeutics, BrainStorm Cell Therapeutics, Brigham and Women's Hospital, Bristol-Myers Squibb, Caladrius Biosciences, Calidi Biotherapeutics, California Institute for Regenerative Medicine, California Stem Cell, Calimmune, Canadian Institutes of Health Research, CareDx, Case Western Reserve University, Case Western Reserve University School of Medicine, CASI Pharmaceuticals, Catalent, Cedars-Sinai Medical Center, CeeTox, Celgene, Cell2in, Cell Care Therapeutics, Cell Cure Neurosciences, Cellect Biotechnology, Cellectis, Cellectis Bioresearch, Cellectricon, Cellerix, Celling Biosciences, CellProThera, Celltex Therapeutics, Cell Therapy Catapult, Cellular Biomedicine, Cellular Dynamics International, Cellzome, Celsis In Vitro Technologies, Celulas Genetica, Censo Biotechnologies, Center for iPS Cells Research and Application, Centogene, Centre for Commercialization of Regenerative Medicine (CCRM), Centre for Drug Research and Development (CDRD), Cephalon, Cesca Therapeutics, CFD Research, CHA Bio & Diostech, Charite-Universitatsmedizin, ChemDiv, Chemizon, Children's Hospital Boston, Children's Hospital of Orange County, Children's Research Institute, China Cord Blood, China PharmaHub, China Southeast University, Chong Kun Dang, Cincinnati Children’s Hospital Medical Center, Cipla, Citius Pharmaceuticals, City of Hope, Cleveland BioLabs, Cleveland Clinic, Cleveland Cord Blood Center, Clontech Laboratories, CNA Development, COARE Biotechnology, Cognate BioServices, Cohen-McNiece Foundation, Columbia University, Cord Blood America, Cordlife, CordVida, Cornell University, Corning, CPC Clinical Research, Creative Medical Technologies, CRISPR Therapeutics, CropLife America, Crown Bioscience, Cryo-Cell International, CSIRO, Curasan, CvergenX, Cynata Therapeutics, Cystinosis Research Foundation, Cytomedix, CytoMed Therapeutics, Cytori Therapeutics, CYTOVIA Therapeutics, Cytovis, Dako, Dana-Farber Cancer Institute, Deepcell, DefiniGEN, Department of Defense, Department of Health and Human Services, DePuy, Dexterity, DiNonA, Dolomite, Dow Chemical, Dow Corning, Duke University, DV Biologics, Ectycell, EdiGene, Eli Lilly, Elixirgen, EMD Millipore, Emerging Healthcare Solutions, ENCell, Entest BioMedical, Epistem, Eppendorf, ERS Genomics, ES Cell International, Eterna Therapeutics, Ethos Discovery, European Commission, European Union, Eutilogics, Evotec, ExCellThera, Exploit Technologies, ExxonMobil, Fast Forward, Fate Therapeutics, Federal Ministry of Education and Research (BMBF), Florey Institute of Neuroscience and Mental Heath, Florica Therapeutics, Florida State University, Fluidigm, Fondazione San Raffaele, Fondazione Telethon, Food and Drug Administration (FDA), Fortis Healthcare, Fraunhofer Institute for Molecular Ecology (IME), Fred Hutchinson Cancer Research Center, Fujifilm, FUJIFILM Cellular Dynamics, Fundacio Clinic, Fusion Antibodies, Gallant Therapeutics, Gamida Cell, GE Healthcare, GenCure, Generex Biotechnology, Genezen, Genome Diagnostics, genOway, Gentium, GenVec, Geron, Gladstone Institutes, GliaMed, Global Alliance for Innovation in Neuroscience, Golden Helix, Golden Meditech, Government of United Kingdom, Grandhope Biotech, Griffith University, GSK, Guangzhou Municipality Tianhe Nuoya Bio-engineering, Hadasit Bioholdings, Hadasit Medical Research Services and Development, Hadassah Medical Center, Hadassah University, Haihe Laboratory of Cell Ecosystem, Hamad Bin Khalifa University, Hamilton Thorne, Hamner Institutes for Health Sciences, Harvard Medical School, Harvard Stem Cell Institute, Harvard University, Healios K.K., Healthpoint, Heartseed, Heat Biologics, Hemogenix, Hemostemix, HepaTx, Heraeus, Histogen, Hoffmann La Roche, Hong Kong Baptist University, Horizon Discovery, Hospital for Sick Children, Huapont Pharma, Hubrecht Institute, Humacyte, Human Life CORD Japan, Human Longevity, Humex Medical, iCo Therapeutics, ID Pharma, Ilika Technologies, Illumina, ImageIQ, ImmuneRegen BioSciences, Immunis, ImmunityBio, ImmunoCellular Therapeutics, Implant Therapeutics, Indiana University, Indian Immunological, Innovation Australia Research and Development, Innovative Medicines Initiative (IMI), Insitro, Instem, Institute of Cancer Research, Institute Of Molecular Biotechnology, Integrated Biobank of Luxembourg, Intellia Therapeutics, IntelliCell BioSciences, Intercytex, International Stem Cell, Intrexon, Invitrx Therapeutics, InVivo Therapeutics, Ionis Pharmaceuticals, iPS Academia Japan, ISee3D, Israeli National Authority for Technological Innovation, Jadi Cell, Jain Foundation, Janssen Biotech, Japan Science and Technology Agency, Jasper Therapeutics, Jazz Pharmaceuticals, JCR Pharmaceuticals, Jian An Pharmaceuticals, Johns Hopkins University, Johnson & Johnson Innovation, Juvenile Diabetes Research Foundation, Keck School of Medicine of USC, KellBenx, Kempbio, Kensey Nash, Kiadis Pharma, Kings College London, Kite Pharma, Kumamoto University, Kyoto Biken, Kyoto University, Lab21, Laboratory Corporation of America, La Jolla Pharmaceutical, Lee Moffitt Cancer Center, Lehigh University, Leiden University, Lentigen, Leona M and Harry B Helmsley Charitable Trust, Leukemia & Lymphoma Society, Life Technologies, Life Technologies Corporation, Lineage Cell Therapeutics, Longeveron, Lonza, Loughborough University, Lucigen, Lucy Biotech, Lupus Foundation of America (LFA), Macquarie University, Magenta Therapeutics, Maryland Stem Cell Research Fund, Maryland Technology Development Corporation, Massachusetts General Hospital, Matricel, Maxcyte, Mayo Clinic, McEwen Centre for Regenerative Medicine, McGill University, MD Anderson Cancer Center, Medac, Medexus Pharmaceuticals, Medical College of Wisconsin, Medical Research Council, Medical University South Carolina, Medistem, Mekonos, Memorial Sloan Kettering Cancer Center, Merck and Co, Merus, Mesoblast, Metrion Biosciences, Michael J Fox Foundation, Midas Mediscience, Miltenyi Biotec, Minerva Biotechnologies, Ministry of Industry and Trade of the Russian Federation, Miracle Babies, Miragen Therapeutics, Mirna Therapeutics, Mokshagundam Biotechnologies, Molecular Imaging Research, Molecular Templates, Monash University, Montreal Heart Institute, MPI Research, Multiclonal Therapeutics, Munich Technical University, Murdoch Childrens Research Institute, myTomorrows, NanoCellect Biomedica, Nano Dimension, nanoRanch, Nanotope, NantKwest, Nanyang Technological University, National Cancer Institute, National Center for Advancing Translational Sciences (NCATS), National Center for Regenerative Medicine, National Eye Institute, National Health and Medical Research Council, National Heart, Lung and Blood Institute, National Institute of Allergy and Infectious Diseases, National Institute of Biomedical Innovation, National Institute on Aging, National Institutes of Health, National Institutes of Health Center for Regenerative Medicine, National Psoriasis Foundation, National Research Council Industrial Research Assistance Program, National Science Foundation, National Stem Cell Foundation, National University of Ireland, Galway (NUI Galway), Ncardia, Netherlands Government, NeuralStem, Neural Stem Cell Institute, Neusentis, Nikon CeLL Innovation, Northwestern University, Novartis, Novellus Therapeutics, Novo Nordisk, Nuclea Biotechnologies, NuPotential, NuVasive, Nvidia, Obagi Medical Products, Ocata Therapeutics, OcellO, Octane Biotech, Ocumension Therapeutics, Omeros, OncoImmune, OncoMed Pharmaceuticals, OptoRobotix, Orbsen Therapeutics, Orchard Therapeutics, Oregon Health Sciences University, Organovo, Orgenesis, ORIG3N, Orthocell, OrthoCyte, Orthopaedic Research and Education Foundation, Osiris Therapeutics, Oxford Biodynamics, Parcell Laboratories, Parcell Spine, Pathways to Stem Cell Science, PAWS Pet Company, PerkinElmer, Pfizer, PharmaCell, PharmaCyte Biotech, Philogen, Pikamab, Plasticell, Platelet BioGenesis, Pluriomics, Pluristem Therapeutics, Pluristyx, Polyplus Transfection, PreCerv, Primera Bioscience Research, Princess Margaret Hospital, Pro-Cure Therapeutics, ProBioGen, Procella Therapeutics, Procyon Technologies, Progenitor Cell Therapy, Promega, Promosome, Protein Genomics, Proteonomix, P T Kalbe Farma, Pulthera, QIAGEN, Q Therapeutics, Quintiles, RainDance Technologies, Ramot at Tel Aviv University, R Biomedical, RecipharmCobra Biologics, Recopharma, ReCyte Therapeutics, Regen BioPharma, Regenerative Sciences, Regenerex, Regenetech, Regeneus, Reinnervate, ReNeuron, Renovacare, RenovoCyte, ReproCell, Research Products Development Company, RHEI Pharmaceuticals, RNL Bio, Roche, Roche Applied Science, Rockefeller University, Rohto Pharmaceutical, RoosterBio, Roslin Cellab, Roslin Cells, Roslin Institute, Royal Children’s Hospital, Royal College of Surgeons (Ireland), RST Biomedikal Sanayi, RTI Surgical, Rubedo Life Sciences, Rutgers University, RxBio, Salk Institute, Sana Biotechnology, SanBio, Sanford Burnham Institute, Sanford Consortium for Regenerative Medicine, Sangamo Therapeutics, Sankara Nethralaya, Sanofi, Sanofi-Aventis, San Raffaele Telethon Institute for Gene Therapy, Scaled Biolabs, Schepens Eye Research Institute, SCM Pharma, ScreenCell, Scripps Genomic Medicine, Seattle Childrens Research Institute, Selexis, SeqWright, Seres Therapeutics, Service Francophone du Sang, Shanghai Cell Therapy Group, Shanghai Jia Fu Medical Apparatus, Sharp Edge Labs, Shenogen Pharma, Shoreline Biosciences, Shrink Chips, Shrink Nanotechnologies, Sigma-Aldrich, Sigma-Tau, Sigma Life Science, SimonMed Imaging, Sirion Biotech, Sirius Genomics, Sirona Biochem, Sistemic, Sitoa, Smartwise, Smith & Nephew, South Texas Blood & Tissue Center, Spectrum Pharmaceuticals, Spinogenix, Stanford University, Stellar Pharmaceuticals, StemBioSys, StemCardia, Stem Cell & Regenerative Medicine International (SCRMI), Stem Cell Medicine, StemCells, Stem Cells 21, StemCell Systems, Stemcell Technologies, Stem Cell Therapeutics, StemCyte, Stemedica Asia, Stemedica Cell Technologies, Stem Genomics, Stemina Biomarker Discovery, Stemmatters, Stemnion, Stempeutics, Steven M. Schwartzberg Memorial Fund, Stryker, Suneva Medical, Superview Biotechnology, Swedish Orphan Biovitrum, SwitchGear Genomics, Synterys, System Biosciences, Taconic Biosciences, TaiRx, Takara Bio, Takeda Pharmaceutical, TAP Biosystems, Targazyme, Taxus Cardium Pharmaceuticals, Technology Strategy Board (UK), Technology University Dresden, Teijin, Temple University, Terumo Blood and Cell Technologies, TET Systems, Teva Pharmaceutical Industries, The Automation Partnership, The Global Stem Cell and Regenerative Medicine Acceleration Center (GSRAC), The New York Stem Cell Foundation, TheraBiologics, Theragent, Therakine, Therapeutic Solutions International, The Regents of the University of California, ThermoGenesis, The UK Stem Cell Bank, Thomas Jefferson University, Thrive Bioscience, TiGenix, Tissue Genesis, Tissue Regeneration Therapeutics (TRT), Tiziana Life Sciences, TONIX Pharmaceuticals, Transgenomic, Transposagen Biopharmaceuticals, TreeFrog Therapeutics, Trestle Biotherapeutics, Trillium Therapeutics, Tri Phuoc, TTFactor, Tu Dresden, U CAN-CER VIVE Foundation, UCB, Unilever, University Ann & Robert H. Lurie Children’s Hospital, University Campus Suffolk, University City Science Center, University College London, University Health Network, University Hospitals Case Medical Center, University of Adelaide, University of Birmingham, University of California, University of California, Davis, University of California, San Diego, University of California, San Diego (UCSD) School of Medicine, University of California Irvine, University of California Los Angeles, University of California San Francisco, University of Cambridge, University of Cologne, University of Dundee, University of Edinburgh, University of Florida, University of Louisville, University of Maryland, University of Maryland School of Medicine, University of Massachusetts, University of Massachusetts, Amherst, University of Massachusetts Medical School, University of Medicine and Dentistry of New Jersey (UMDNJ), University of Melbourne, University of Miami Miller School of Medicine, University of Michigan, University of Minnesota, University of Montreal Pharmacogenomics Centre, University of Notre of Dame, University of Oxford, University of Pennsylvania, University of Pittsburgh, University of Pittsburgh Medical Center, University of Queensland, University of Rochester Medical Center, University of Sheffield, University of South Carolina, University of Southern California, University of Sydney, University of Tokyo, University of Tubingen, University of Utah, University of Washington, University of Wisconsin-Madison, University of York, US Government, US Spine, US Stem Cell Clinic, Vascugen, Vatican, Vectalys, Vertex Pharmaceuticals, Vet-Stem, ViaCord, ViaCyte, Virdante Biophrmaceuticals, Viscofan BioEngineering, VistaGen Therapeutics, VitaThreads, Vitro Diagnostics, Vitrolife, Vivalis, Vivo Biosciences, Vor Biopharma, Wake Forest University, WCTE, Weill Cornell Medical College, Wellcome Trust, Wellcome Trust Sanger Institute, W L Gore, Worcester Polytechnic Institute (WPI), Yale University, Yeda Research and Development Company, Yorkshire Cancer Research, Yumanity Therapeutics

About Current Partnering

A definitive, evidence-based approach to dealmaking intelligence

Current Partnering is the industry-leading provider of pharmaceutical and biotech dealmaking intelligence, delivering a clear, structured, and evidence-based view of how partnerships are designed, negotiated, and executed in practice.

Our reports combine comprehensive deal coverage, structured data analysis, and contract-level insight, enabling a deeper understanding of how financial terms, rights, and responsibilities are defined across real-world transactions.

All reports are updated every six months, ensuring users have access to the latest deal activity, trends, and market developments.

---

Our methodology

Built on a continuously updated proprietary database

All analysis is underpinned by Current Agreements, our proprietary deals and alliances database which is updated daily by our analysts as new transactions are announced globally.

Deal records are continuously reviewed and enriched as additional information becomes available, ensuring accuracy, completeness, and relevance.

---

Comprehensive and verifiable data sourcing

Deal data is sourced from publicly available industry disclosures, including:

• Company press releases and announcements
• SEC filings and equivalent regulatory disclosures
• Company and investor presentations
• Conference materials and company websites

All sources are captured and referenced, enabling full transparency and user verification.

---

Broad coverage across deal types and structures

Current Partnering provides comprehensive coverage across a wide range of deal types, including but not limited to:

• Licensing and co-development
• Research and collaborative R&D
• Manufacturing, supply, and distribution
• Commercialisation and co-promotion
• Equity investments, joint ventures, and asset transactions
• Options, royalties, and financing agreements

This breadth ensures a complete view of how partnerships are structured across the life sciences sector.

---

Structured, standardised analysis

Every deal is analysed using a consistent framework, capturing (where disclosed):

• Financial terms — including upfront payments, milestones, and royalties
• Rights allocation — development, manufacturing, and commercialization responsibilities
• Deal structure — exclusivity, territorial scope, and agreement type
• Contractual provisions — clauses defining risk, control, and value-sharing

Each deal record is fully categorised, including data fields such as:

• Therapy area and technology type
• Stage of development
• Asset type and deal components
• Geographic scope and exclusivity
• Source documentation, including press releases and SEC filings

---

Financial normalisation for comparability

All financial values are standardised to USD using the exchange rate at the time of deal announcement, enabling consistent comparison of deal terms across geographies.

---

Contract-level insight

Where available, reports include direct access to underlying agreement documents, providing visibility into how deals are constructed in practice.

This enables users to understand:

• How financial mechanisms are defined and triggered
• How responsibilities are operationalised between parties
• How flexibility, risk, and control are allocated within agreements

---

Designed for real-world application

Current Partnering reports are built to support business-critical decision-making across the life sciences ecosystem, including:

• Pharmaceutical and biotech companies — benchmarking deals, structuring transactions, and supporting licensing strategy
• Investment firms and venture capital — assessing deal benchmarks, valuation expectations, and partner behaviour
• Advisory, legal, and consulting firms — supporting client engagements with real-world precedent and contract-level insight

Common use cases include:

• Benchmarking comparable transactions
• Supporting valuation and deal structuring
• Preparing for negotiations
• Evaluating potential partners
• Informing internal strategy with real-world evidence

---

A trusted industry reference

With a long track record in the sector, Current Partnering is relied upon by leading pharmaceutical companies, emerging biotechs, investors, and advisory firms as a trusted source of dealmaking intelligence.

By combining proprietary data, rigorous methodology, and contract-level insight, our reports provide a reliable and authoritative foundation for understanding how deals are structured, negotiated, and valued.